Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christoph Bode

Showing results (1-10 of 600) with videos related to

Pageof 60
Sort By:
MMW Fortschritte Der Medizin|June 29, 2005
[For my coronary heart disease patients I strive for a 70 mg/dl LDL level (interview by Dr. med. Dirk Einecke)]Christoph Bode
Hamostaseologie|December 7, 2007
[Innovations in thrombolytic therapy in heart and coronary diseases]Christoph Bode
Cardiovascular Research|April 22, 2016
Hsp70 preventing thrombosis: benefit without burden?Daniel Duerschmied, Christoph Bode
Current Opinion in Investigational Drugs (London, England : 2000)|August 26, 2009
Novel antiplatelet therapies following percutaneous coronary interventionsIngo Ahrens, Christoph Bode
Herz|December 7, 2005
[Future developments in the therapy of acute ST segment elevation myocardial infarction]Martin Moser, Christoph Bode
Journal of Thrombosis and Thrombolysis|November 30, 2016
Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillationAndreas Zirlik, Christoph Bode
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|May 6, 2009
EUROSCORE: still gold standard or less?Christoph Bode, Malte Kelm
Journal of Blood Medicine|March 5, 2014
Clinical utility of rivaroxaban in stroke prevention associated with nonvalvular atrial fibrillation - patient considerationsIngo Ahrens, Christoph Bode
Thrombosis and Haemostasis|July 31, 2018
Life-Saving Therapy versus Symptom Relief: Anti-Platelet Agents and Opioids in Coronary InterventionDaniel Duerschmied, Christoph Bode
European Heart Journal|November 16, 2004
Impaired glucose tolerance-a new risk factor?Diethelm Tschöpe, Christoph Bode
Pageof 60

Showing results (1-10 of 600) with videos related to

Sort By:
Pageof 60
MMW Fortschritte Der Medizin|June 29, 2005
[For my coronary heart disease patients I strive for a 70 mg/dl LDL level (interview by Dr. med. Dirk Einecke)]Christoph Bode
Hamostaseologie|December 7, 2007
[Innovations in thrombolytic therapy in heart and coronary diseases]Christoph Bode
Cardiovascular Research|April 22, 2016
Hsp70 preventing thrombosis: benefit without burden?Daniel Duerschmied, Christoph Bode
Current Opinion in Investigational Drugs (London, England : 2000)|August 26, 2009
Novel antiplatelet therapies following percutaneous coronary interventionsIngo Ahrens, Christoph Bode
Herz|December 7, 2005
[Future developments in the therapy of acute ST segment elevation myocardial infarction]Martin Moser, Christoph Bode
Journal of Thrombosis and Thrombolysis|November 30, 2016
Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillationAndreas Zirlik, Christoph Bode
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|May 6, 2009
EUROSCORE: still gold standard or less?Christoph Bode, Malte Kelm
Journal of Blood Medicine|March 5, 2014
Clinical utility of rivaroxaban in stroke prevention associated with nonvalvular atrial fibrillation - patient considerationsIngo Ahrens, Christoph Bode
Thrombosis and Haemostasis|July 31, 2018
Life-Saving Therapy versus Symptom Relief: Anti-Platelet Agents and Opioids in Coronary InterventionDaniel Duerschmied, Christoph Bode
European Heart Journal|November 16, 2004
Impaired glucose tolerance-a new risk factor?Diethelm Tschöpe, Christoph Bode
Pageof 60